Next Issue
Volume 2, IECG 2018
Previous Issue
Volume 2, ICEM 2018
proceedings-logo

Journal Browser

Journal Browser

Table of Contents

Proceedings, 2018, ICT 2018

The 25th Biennial International Congress on Thrombosis

Venice, Italy | 23–26 May 2018

Issue Editors: Paolo Prandoni and Vittorio Pengo


  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Readerexternal link to open them.
Cover Story (view full-size image) This Issue collates the abstracts presented at the 25th Biennial International Congress on [...] Read more.
Order results
Result details
Select all
Export citation of selected articles as:

Abstract Book

Open AccessMeeting Report
Abstracts of the 25th Biennial International Congress on Thrombosis
Proceedings 2018, 2(9), 531; https://doi.org/10.3390/proceedings2090531 - 12 Oct 2018
Viewed by 843
Abstract
This Issue collates the abstracts presented at the 25th Biennial International Congress on Thrombosis held on 23–26 May 2018. Prevention and treatment of thromboembolic events is a main issue in medicine that involves all the components of the health care system. Recently, a [...] Read more.
This Issue collates the abstracts presented at the 25th Biennial International Congress on Thrombosis held on 23–26 May 2018. Prevention and treatment of thromboembolic events is a main issue in medicine that involves all the components of the health care system. Recently, a strong boost in this field came from the introduction of new antithrombotic agents whose use is expanding with the need for more information obtained by real-life studies. Thus, ICT 2018 was an important venue to compare clinical experiences and learn new advances in basic and pharmacological sciences. Full article

Conference Research

Jump to: Abstract Book

Open AccessProceedings
Genetic Testing for Inherited Thrombophilia: 20 Years of Experience in a University and Tertiary Care Centre
Proceedings 2018, 2(9), 527; https://doi.org/10.3390/proceedings2090527 - 19 Jul 2018
Viewed by 628
Abstract
Inherited thrombophilias are a group of clinical conditions in which there is a genetic variant defect associated with a predisposition to thrombosis. Genetic testing for inherited thrombophilias has been used in the diagnosis of specific thrombophila at our centre for the last 20 [...] Read more.
Inherited thrombophilias are a group of clinical conditions in which there is a genetic variant defect associated with a predisposition to thrombosis. Genetic testing for inherited thrombophilias has been used in the diagnosis of specific thrombophila at our centre for the last 20 years, this work will summarize our experience. Full article
Open AccessProceedings
Initial Results of Oral Thrombolytic Agent Clinical Application
Proceedings 2018, 2(9), 530; https://doi.org/10.3390/proceedings2090530 - 20 Jul 2018
Viewed by 563
Abstract
At the moment, there is no oral thrombolytic drug on the world pharmaceutical market. The drug Trombovazim, which has a thrombolytic effect under oral administration, has been registered in Russia. It differs from all thrombolytics—it has a fundamentally different mechanism of action. It [...] Read more.
At the moment, there is no oral thrombolytic drug on the world pharmaceutical market. The drug Trombovazim, which has a thrombolytic effect under oral administration, has been registered in Russia. It differs from all thrombolytics—it has a fundamentally different mechanism of action. It is not an activator of plasminogen. It independently dissolves a thrombus. It is a direct thrombolytic. The article presents the materials of the initial studies of the drug Trombovazim. Full article
Open AccessProceedings
An Italian Registry on Risk Factors for Venous Thromboembolism in Blood Donors Clinicaltrials. Gov: Nct03282747
Proceedings 2018, 2(9), 532; https://doi.org/10.3390/proceedings2090532 - 25 Jul 2018
Viewed by 527
Abstract
A registry-based study to evaluate prevalence of common risk factors for vein thrombosis among healthy subjects. Full article
Open AccessProceedings
Evaluation of the Plasmic Score for the Prediction of Adamts13 Activity in Patients with Thrombotic Microangiopathies
Proceedings 2018, 2(9), 533; https://doi.org/10.3390/proceedings2090533 - 26 Jul 2018
Cited by 1 | Viewed by 552
Abstract
The PLASMIC score for the prediction of a likelihood of a severe ADAMTS13 deficiency represents a valid pre-test diagnostic tool to identify patients with thrombotic thrombocytopenic purpura. Full article
Open AccessProceedings
Variations in Mean Platelet Volume in Patients with Helicobacter pylori Infection before and after Eradication, Way before Immune Thrombocytopenia?
Proceedings 2018, 2(9), 529; https://doi.org/10.3390/proceedings2090529 - 27 Jul 2018
Viewed by 588
Abstract
Helicobacter pylori (H. pylori) and immune thrombocytopenia (ITP) association is well known and eradication treatment has its place in both treatment guidelines. Since H. pylori eradication is followed by an increase in platelet counts in patients with immune thrombocytopenia, it is [...] Read more.
Helicobacter pylori (H. pylori) and immune thrombocytopenia (ITP) association is well known and eradication treatment has its place in both treatment guidelines. Since H. pylori eradication is followed by an increase in platelet counts in patients with immune thrombocytopenia, it is suggested that H. pylori be examined and treated if infection is present. There is only one study that demonstrated a relation between H. pylori and platelet indices in individuals with normal platelet counts. In this study, we aimed to investigate the effects of H. pylori infection on platelet count and mean platelet volume, which is a sign of increased platelet destruction in patients with normal platelet counts. We evaluated the data of 106 patients with urease test positivity before the eradication of bacteria and urea breath test negative after the eradication, in a retrospective manner. Mean platelet count in patients before the eradication treatment was 256.730 ± 66.380/mm3. After H. pylori was eradicated, it has been observed that the mean platelet count increased to 287.080 ± 59.240/mm3. Mean MPV of patients before and after eradication treatment were 9.35 ± 1.63 fL and 8.61 ± 1.48 fL. Mean MPV was higher when patients were infected with H. pylori. This study showed that there is an increase in platelet counts and a decrease in MPV levels with the eradication of the H. pylori. Our study is the first to investigate changes of mean platelet volume and platelet count before and after eradication of H. pylori infection in individuals with normal platelet counts. Full article
Open AccessProceedings
Predicting Recurrence after a First Unprovoked Venous Thromboembolism: Retrospective Validation of the DAMOVES Score
Proceedings 2018, 2(9), 528; https://doi.org/10.3390/proceedings2090528 - 30 Jul 2018
Viewed by 427
Abstract
Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate. However, in one-third of patients with unprovoked venous thromboembolism, the risk of [...] Read more.
Unprovoked venous thromboembolism is associated with a 5 to 27% annual risk of recurrence after discontinuation of anticoagulation, and indefinite anticoagulation is recommended if the bleeding risk is low to moderate. However, in one-third of patients with unprovoked venous thromboembolism, the risk of recurrence is so low (<5% per year) that anticoagulant therapy >3–6 months may not be necessary. Several prediction rules were derived to identify patients with unprovoked venous thromboembolism who have a low recurrence risk. In 2016, we presented our results of the original DAMOVES, a nomogram for prediction of recurrence in an individual patient with unprovoked venous thromboembolism. The aim of this study was to externally validate this nomogram in patients with unprovoked venous thromboembolism. Full article
Previous Issue
Next Issue
Back to TopTop